β受体阻滞剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及他汀类药物对植入式心脏复律除颤器患者死亡率的影响。
Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators.
作者信息
Lai Hoang M, Aronow Wilbert S, Kruger Adam, Desai Harit, Amin Harshad, Frishman William H, Cohen Martin, Sorbera Carmine
机构信息
Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY, USA.
出版信息
Am J Cardiol. 2008 Jul 1;102(1):77-8. doi: 10.1016/j.amjcard.2008.02.103. Epub 2008 Apr 22.
Nine hundred sixty-five patients (mean age 70 years) with implantable cardioverter-defibrillator were followed for 32 +/- 33 months for all-cause mortality. Death occurred in 73 of 515 patients (13%) treated with beta blockers (group 1), in 84 of 494 patients (17%) treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (group 2), in 56 of 402 patients (14%) treated with statins (group 3), in 40 of 227 patients (18%) treated with amiodarone (group 4), in 5 of 26 patients (19%) treated with sotalol (group 5), and in 64 of 265 patients (24%) treated with no beta blocker, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, statin, amiodarone, or sotalol (group 6) (p <0.001 for group 1 vs group 6 and group 3 vs group 6, p <0.02 for group 2 vs group 6). In conclusion, patients with implantable cardioverter-defibrillators should be treated with beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins to reduce mortality.
965例植入式心脏复律除颤器患者（平均年龄70岁）接受了32±33个月的全因死亡率随访。在515例接受β受体阻滞剂治疗的患者（第1组）中，73例（13%）死亡；在494例接受血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂治疗的患者（第2组）中，84例（17%）死亡；在402例接受他汀类药物治疗的患者（第3组）中，56例（14%）死亡；在227例接受胺碘酮治疗的患者（第4组）中，40例（18%）死亡；在26例接受索他洛尔治疗的患者（第5组）中，5例（19%）死亡；在265例未接受β受体阻滞剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂、他汀类药物、胺碘酮或索他洛尔治疗的患者（第6组）中，64例（24%）死亡（第1组与第6组、第3组与第6组比较，p<0.001；第2组与第6组比较，p<0.02）。总之，植入式心脏复律除颤器患者应接受β受体阻滞剂、血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂以及他汀类药物治疗以降低死亡率。
Zotero 插件